Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Katherine A. Guthrie et al.|Journal of Clinical Oncology|2020Cited by 391
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeChristine M. Parseghian, Scott Kopetz, Jonathan M. Loree et al.|Annals of Oncology|2018Cited by 239
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping PanelJason Willis, Justin I. Odegaard, Martina I. Lefterova et al.|Clinical Cancer Research|2019Cited by 237
Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung AdenocarcinomaMaria Schwaederlé, Razelle Kurzrock, Sandip Pravin Patel et al.|Clinical Cancer Research|2017Cited by 147
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D. Engstrom, James G. Christensen, Nir Peled et al.|Clinical Cancer Research|2017Cited by 147